Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
Su CT, Nizialek E, Berchuck JE, Vlachostergios PJ, Ashkar R, Sokolova A, Barata PC, Aggarwal RR, McKay RR, Agarwal N, McClure HM, Nafissi N, Bryce AH, Sartor O, Sayegh N, Cheng HH, Adra N, Sternberg CN, Taplin ME, Cieslik M, Alva AS, Antonarakis ES.
Su CT, et al. Among authors: sartor o.
Prostate. 2023 Feb;83(3):227-236. doi: 10.1002/pros.24454. Epub 2022 Nov 16.
Prostate. 2023.
PMID: 36382533
Free PMC article.